Potential Repurposing of Known Drugs as Potent Bacterial β-Glucuronidase Inhibitors
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
The active metabolite of the chemotherapeutic irinotecan, SN-38, is detoxified through glucuronidation and then excreted into the gastrointestinal tract. Intestinal bacteria convert the glucuronidated metabolite back to the toxic SN-38 using β-glucuronidase (GUS), resulting in debilitating diarrhea. Inhibiting GUS activity may relieve this side effect of irinotecan. In this study, we sought to determine whether any known drugs have GUS inhibitory activity. We screened a library of Food and Drug Administration-approved drugs with a cell-free biochemical enzyme assay using purified bacterial GUS. After triage, five drugs were confirmed to inhibit purified bacterial GUS. Three of these were the monoamine oxidase inhibitors nialamide, isocarboxazid, and phenelzine with average IC(50) values for inhibiting GUS of 71, 128, and 2300 nM, respectively. The tricyclic antidepressant amoxapine (IC(50) = 388 nM) and the antimalarial mefloquine (IC(50) = 1.2 µM) also had activity. Nialamide, isocarboxazid, and amoxapine had no significant activity against purified mammalian GUS but showed potent activity for inhibiting endogenous GUS activity in a cell-based assay using living intact Escherichia coli with average IC(50) values of 17, 336, and 119 nM, respectively. Thus, nialamide, isocarboxazid, and amoxapine have potential to be repurposed as therapeutics to reduce diarrhea associated with irinotecan chemotherapy and warrant further investigation for this use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
Self-citationA Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Stein, A., Voigt, W., & Jordan, K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009355164 · Cited by 431 · cited 3×
“Irinotecan (also called CPT-11) is frequently used to treat colon, lung, and brain cancer, and it has also been used against refractory forms of leukemia and lymphoma.1 Irinotecan functions as a prodrug, having a carbamate-linked dipiperidino group that significantly increases its solubility and bioavailability.2 In v…”
BackgroundPizzolato, J. F., & Saltz, L. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13780-4 · Cited by 359
A High-Throughput Screen for Aggregation-Based Inhibition in a Large Compound Library
Feng, B. Y., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B. K., & Austin, C. P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061317y · Cited by 358
Annales Universitatis Mariae Curie-Skłodowska
Lublinie, U. M. C.-S. W. (2001) · Cited by 211
Miley, M. J., Zielinska, A. K., Keenan, J. E., Bratton, S. M., Radominska-Pandya, A., & Redinbo, M. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.03.066 · Cited by 198
Pharmacogenetics of irinotecan metabolism and transport: An update
Smith, N. F., Figg, W. D., & Sparreboom, A. (2006) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.045 · Cited by 190
Cited by
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Gut microbiome interactions with drug metabolism, efficacy, and toxicity
Wilson, I. D., & Nicholson, J. K. (2017) · Translational Research · doi:10.1016/j.trsl.2016.08.002 · Cited by 656
Irinotecan: 25 years of cancer treatment
Bailly, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104398 · Cited by 456
Therapeutic significance of β-glucuronidase activity and its inhibitors: A review
Awolade, P., Cele, N., Kerru, N., Gummidi, L., Oluwakemi, E., & Singh, P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111921 · Cited by 179
Chamseddine, A. N., Ducreux, M. P., Armand, J., Paolettí, X., Satar, T., Paci, A., & Mir, O. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.002 · Cited by 124
Metadata
- Authors
- Ahmad, S., Hughes, M. A., Yeh, L.-A., & Scott, J. E.
- Affiliations
- North Carolina Central University (US)
- Corresponding author
- Scott, John E.
- ORCID
- Ahmad, Syed
- Venue
- SLAS Discovery
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 17
- Issue
- 7
- Pages
- 957-965
- ISSN
- 2472-5552 (ISSN-L)
- PMC
- PMC8284931
- OpenAlex
- W2162578613
- Cited by
- 44
- References
- 31
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 1 · 2021: 7 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 1
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3545 d)
- Locations
- SLAS DISCOVERY (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1sc2gm081129-01)
- National Institute of General Medical Sciences (1SC2GM081129, SC2 GM081129)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- drug repurposing, β-glucuronidase inhibition, irinotecan, SN-38, glucuronidation, nialamide, isocarboxazid, phenelzine, amoxapine, mefloquine, monoamine oxidase inhibitors, tricyclic antidepressants, Escherichia coli, drug screening
- MeSH terms
- Irinotecan, Amoxapine, Antineoplastic Agents, Phytogenic, Camptothecin, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Glucuronidase, Isocarboxazid, Monoamine Oxidase Inhibitors, Nialamide, Phenelzine, Mefloquine, Escherichia coli Proteins, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Repurposing of Known Drugs as Potent Bacterial β-Glucuronidase Inhibitors. https://app.cochat.ai/papers/10.1177/1087057112444927
- The paper
- Ahmad, S., Hughes, M. A., Yeh, L.-A., & Scott, J. E. (2012). Potential Repurposing of Known Drugs as Potent Bacterial β-Glucuronidase Inhibitors. SLAS Discovery. https://doi.org/10.1177/1087057112444927
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.